Patent US5352461A successfully refreshed from Google Patents.
US5352461A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Self assembling diketopiperazine drug delivery system
Assignee: Mannkind Corp
•
Filing: 1992-03-11
•
Granted: 1994-10-04
•
Expires: 2012-03-11
Abstract
Abstract Drug delivery systems have been developed based on the formation of diketopiperazine (or analogs) microparticles. In the preferred embodiment the microparticle is stable at low pH and disintegrates at physiological pH, and is particularly useful for oral drug delivery. In the most preferred embodiment the microparticles are formed in the presence of the drug to be delivered, for example, insulin or heparin. The diketopiperazine synthetic intermediates are preferably formed by cyclodimerization to form diketopiperazine derivatives at elevated conditions under dehydrating conditions, then precipitated with drug to be incorporated into microparticles.
Inventors
- 👤 Robert Feldstein
- 👤 John Glass
- 👤 Solomon S. Steiner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 19:35
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1617
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
64 words
A microparticulate system for drug delivery comprising: diketopiperazine microparticles incorporating a biologically active agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, wherein the microparticles are stable at a first defined pH due to association and precipitation of the diketopiperazines and unstable at a second defined pH due to dissociation of the diketopiperazines.
Claim 2
Dependent Claim
64 words
A microparticulate system for drug delivery comprising: diketopiperazine microparticles incorporating a biologically active agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, wherein the microparticles are stable at a first defined pH due to association and precipitation of the diketopiperazines and unstable at a second defined pH due to dissociation of the diketopiperazines.
Claim 3
Dependent Claim
46 words
The system of claim 1 wherein the diketopiperazine has the general structure ##STR3## wherein the ring atoms X at positions 1 and 4 are either O or N; and at least one of the side-chain substituents R at positions 3 and 6 contains a carboxyl group.
Claim 4
Dependent Claim
28 words
The system of claim 2 wherein the structure is formed from amino acids selected from the group consisting of glutamic acid, aspartic acid, lysine, ornithine and diaminopropionic acid.
Claim 5
Dependent Claim
18 words
The system of claim 3 wherein the structure is selected from the group consisting of 2,5-diketo-3,6-di(aminobutyl)piperazine and 2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine.
Claim 6
Dependent Claim
20 words
The system of claim 1 wherein the microparticles are stable at acidic pH and unstable at a more basic pH.
Claim 7
Dependent Claim
20 words
The system of claim 1 wherein the microparticles are unstable at acidic pH and stable at a more basic pH.
Claim 8
Dependent Claim
11 words
The system of claim 1 wherein the biological agent is insulin.
Claim 9
Dependent Claim
11 words
The system of claim 1 wherein the biological agent is heparin.
Claim 10
Independent Claim
84 words
A method for making a microparticulate system for drug delivery comprising forming diketopiperazines in a solution with a first defined pH at which the diketopiperazines are soluble, adding to the diketopiperazine solution a biologically active agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, imaging agents, and cell specific targeting agents, in a solution having a second defined pH precipitating the diketopiperazines to form microparticles of the diketopiperazines containing the biologically active agent.
Claim 11
Independent Claim
84 words
A method for making a microparticulate system for drug delivery comprising forming diketopiperazines in a solution with a first defined pH at which the diketopiperazines are soluble, adding to the diketopiperazine solution a biologically active agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, imaging agents, and cell specific targeting agents, in a solution having a second defined pH precipitating the diketopiperazines to form microparticles of the diketopiperazines containing the biologically active agent.
Claim 12
Dependent Claim
46 words
The method of claim 9 wherein the diketopiperazine has the general structure ##STR4## wherein the ring atoms X at positions 1 and 4 are either O or N; and at least one of the side-chain substituents R at positions 3 and 6 contains a carboxyl group.
Claim 13
Dependent Claim
52 words
The method of claim 9 wherein the structure is formed from amino acids selected from the group consisting of glutamic acid, aspartic acid, lysine, ornithine and diaminopropionic acid cyclized by blocking free β-amino groups, heating in hot phenol under nitrogen at a temperature equivalent to 175° C., and removing the blocking groups.
Claim 14
Dependent Claim
19 words
The method of claim 11 further comprising succinylating a side chain of the diketopiperazine having a free amino group.
Claim 15
Dependent Claim
18 words
The method of claim 9 wherein the structure is selected from the group consisting of 2,5-diketo-3,6-di(aminobutyl)piperazine and 2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine.
Claim 16
Independent Claim
79 words
A method for administering a biologically active agent to a patient comprising providing the agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, imaging agents, and cell specific targeting agents, in combination with microparticles formed of diketopiperazines, wherein the microparticles are stable at a first defined pH due to association and precipitation of the diketopiperazines and unstable at a second defined pH due to dissociation of the diketopiperazines.
Claim 17
Independent Claim
79 words
A method for administering a biologically active agent to a patient comprising providing the agent selected from the group consisting of proteins, peptides, polysaccharides, lipids, lipopolysaccharides, nucleic acids and other biologically active organic molecules, imaging agents, and cell specific targeting agents, in combination with microparticles formed of diketopiperazines, wherein the microparticles are stable at a first defined pH due to association and precipitation of the diketopiperazines and unstable at a second defined pH due to dissociation of the diketopiperazines.
Claim 18
Dependent Claim
27 words
The method of claim 14 wherein the agent is selected from the group consisting of hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antivirals, antisense, antigens, and antibodies.
Claim 19
Dependent Claim
15 words
The method of claim 14 wherein the microparticles are further encapsulated within an enteric coating.
Claim 20
Dependent Claim
20 words
The method of claim 14 wherein the microparticles are stable at acidic pH and unstable at neutral or basic pH.
Claim 21
Dependent Claim
20 words
The method of claim 14 wherein the microparticles are unstable at acidic pH and stable at neutral or basic pH.
Claim 22
Dependent Claim
11 words
The method of claim 14 wherein the biological agent is insulin.
Claim 23
Dependent Claim
11 words
The method of claim 14 wherein the biological agent is heparin.
References Cited (Backward Citations)
GB1155036A
Cited
GB1255805A
Cited
FR2145555A1
Cited
US4400330A
Cited
EP0216744A2
Cited
US4925673A
Cited
EP0284039A2
Cited
EP0333523A2
Cited
EP0350246A2
Cited
US4976968A
Cited
US4983402A
Cited
WO1991006287A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-10-03 | 1998-04-04 | 1998-10-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-10-03 | 2002-04-04 | 2002-10-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-10-03 | 2006-04-04 | 2006-10-04 | $7700.00 | Window Closed / Lapsed |